Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer

Gynecologic Oncology

Volumn 125, Issue 2, 2012, Pages 292-296

  Katanyoo, Kanyarat ^a   Sanguanrungsirikul, Sompol ^b   Manusirivithaya, Sumonmal ^a  

^a NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Adenocarcinoma; Cervical cancer; Squamous cell carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; THERAPY EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84859577341     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.01.034     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:1-22.
2. Moore MA, Attasara P, Khuhaprema T, Le TN, Nguyen TH, Raingsey PP, et al. Cancer epidemiology in mainland South-East Asia - past, present and future. Asian Pac J Cancer Prev 2010;11(Suppl. 2):67-80.
3. Rose PG, Bundy BN,Watkins EB, Thigpen JT, Deppe G, Miaman MA, et al. Concurrent cisplatin-based chemotherapy and radiotherapy for locally advanced cervical cancer. N Engl J Med 1999;340(15):1144-53. (Pubitemid 29177873)
4. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17(5):1339-48. (Pubitemid 29220838)
5. Eifel PJ,Winter K,Morris M. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01. J Clin Oncol 2004;22(5):872-80. (Pubitemid 41103599)
6. Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 2010;116:140-6.
7. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in United States-a 24- year population-based study. Gynecol Oncol 2000;78:97-105. (Pubitemid 30650338)
8. Sasieni P, Adam J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001;357:1490-3. (Pubitemid 32488859)
9. Kilgore LC, Soong SJ, Gore H, Shingleton HM, Hatch KD, Partridge EE. Analysis of prognostic features in adenocarcinoma of the cervix. Gynecol Oncol 1988;31: 137-48.
10. Lee KBM, Lee JM, Park CY, Cho HY, Ha SY. What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A match case-control study. Int J Gynecol Cancer 2006;16:1569-73. (Pubitemid 44060381)
11. Kleine W, Rau K, Schwoeorer D, Pfleiderer A. Prognosis of the adenocarcinoma of the cervix uteri: a comparative study. Gynecol Oncol 1989;35:145-9. (Pubitemid 19268546)
12. Chen RJ, Lin YH, Chen CA, Huang SC, Chow SN, Hsieh CY. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol 1999;73:184-90.
13. Hopkins M, Morley G. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 1991;77:912-7.
14. Chargui R, Damak T, Khomsi F, Hassouna JB, Chaieb W, Hechiche M, et al. Prognostic factors and clinicopathologic characteristics of invasive adenocarcinoma of the uterine cervix. Am J Obstet Gynecol 2006;194:43-8. (Pubitemid 43017773)
15. Ishikawa H, Nakanishi T, Inoue T, Kuzuya K. Prognostic factors of adenocarcinoma of the uterine cervix. Gynecol Oncol 1999;73:42-6. (Pubitemid 29177597)
16. Baalbergen A, Ewing-Graham PC, Hop WCJ, Struijk P, Helmerhorst ThJM. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol 2004;92: 262-7. (Pubitemid 38147402)
17. Lanciano R, Calkins A, Bundy BN, Parham G, Lucci JA, Moore DH, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology group. J Clin Oncol 2005;23:8289-95.
18. Visioli CB, Zappa M, Ciatto S, Iossa A, Crocetti E. Increasing trends of cervical adenocarcinoma incidence in Italy despite extensive screening programme, 1985-2000. Cancer Detect Prev 2004;28:461-4. (Pubitemid 39568942)
19. Wang SS, Sherman ME, Hildesheim A, Lacey Jr JV, Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in United States for 1976-2000. Cancer 2004;100:1035-44. (Pubitemid 38232621)
20. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Cancer 2005;103(6):1258-64. (Pubitemid 40328098)
21. Irie T, Kiwana J, Minagawa Y, Itamochi H, Sato S, Akeshima R, et al. Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol 2000;26:464-7.
22. Huang Z, Mayr NA, Yuh WTC, Lo SS, Montebello JF, Grecula JC, et al. Predicting outcomes in cervical cancer: a kinetic model of tumor regression during radiation therapy. Cancer Res 2010;70:463-70.
23. Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, et al. Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definition radiotherapy. Int J Radiat Oncol Biol Phys 2011;80:429-36.
24. Oka K, Nakano T, Hoshi T. Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB-1 and PC10 labeling indices. Cancer 1996;77:2280-5. (Pubitemid 26162421)
25. Kim YB, Kim GE, Pyo HR, Cho NH, Keum KC, Lee CG, et al. Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2009;60:822-9. (Pubitemid 39311762)
26. Santin AD, Hermonat PL, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP. Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstet Gynecol 1999;94:78-82. (Pubitemid 29284430)
27. Katanyaoo K, Chantarasri A, Chongtanakon M, Rongsriyam K, Tantivatana T. Pretreatment levels of serum vascular endothelial growth factor do not correlate with outcome in patients with locally advanced cervical cancer. Asian Pac J Cancer Prev 2011;12:1-6.
28. Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease in patients with stage 1B cervical carcinoma. Gynecol Oncol 1995;59:38-44.
29. Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fower WC, et al. Paclitaxel, an active agent in nonsquamous carcinoma of the uterine cervix study. A Gynecologic Oncology Group study. J Clin Oncol 2001;19:1275-8. (Pubitemid 32202530)
30. Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer: a pilot study. Gynecol Oncol 2005;96:805-9. (Pubitemid 40255505)